A systematic review on Richter syndrome: what is the published evidence?

References

• Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 1928;4:285–292.
   PubMedGoogle Scholar
• Lortholary P, Boiron M, Ripault J, Levy JP, Manus A, Bernard J. Chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter's syndrome. Nouv Rev Fr Hematol 1964;78:621–644.
   Google Scholar
• Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:216–228.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Maddocks-Christianson K, Slager SL, Zent CS, et al Risk factors for development of a second malignancy in patients with chronic lymphocytic leukemia. Br J Haematol 2007;139:398–404.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202–215.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as consequence of nucleoside analog therapy for chronic. J Clin Oncol 1999;17:2454–2460.
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007;121:151–156.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P, et al Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009;27:904–910.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the german chronic lymphocytic leukemia study group. J Clin Oncol 2009;27:3994–4001.
   PubMed Web of Science ®Google Scholar
• von Elm E, Costanza MC, Walder B, Tramer MR. More insight into the fate of biomedical meeting abstracts: a systematic review. BMC Med Res Method 2003;3:12–18.
   PubMedGoogle Scholar
• Tsimberidou A-M, O'Brien S, Khouri I, et al Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:2343–2351.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448–454.
   PubMed Web of Science ®Google Scholar
• Thornton PD, Bellas C, Santon A, et al Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leukemia Res 2005;29:389–395.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004;40:383–389.
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, et al CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 2008;111:5646–5653.
   PubMed Web of Science ®Google Scholar
• Rossi D, Drandi D, Genuardi E, et al Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia 2009;23:1062–1072.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Cerri M, et al Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15:4415–4422.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Mao Z, Quintanilla-Martinez L, Raffeld M, et al IgVH mutational status and clonality analysis of Richter's transformation. Am J Surg Pathol 2007;31:1605–1614.
   PubMed Web of Science ®Google Scholar
• Cobo F, Rosiñol L, Martínez A, et al Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. Br J Haematol 2002;119:484–487.
   PubMed Web of Science ®Google Scholar
• Bruzzi JF, Macapinlac H, Tsimberidou AM, et al Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267–1273.
   PubMed Web of Science ®Google Scholar
• Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008;142:709–716.
   PubMed Web of Science ®Google Scholar
• Parrens M, Sawan B, Dubus P, et al Primary digestive Richter's syndrome. Modern Pathol 2001;14:452–457.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, O'Brien SM, Kantarjian HM, et al Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyper-CVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001;42:329–337.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, et al Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocytemacrophage- colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine refractory chronic lymphocytic leukemia. Cancer 2003;97:1711–1720.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196–203.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004;100:2195–2200.
   PubMed Web of Science ®Google Scholar